Is Edgewise Therapeutics, Inc. (EWTX) a Buy, Sell, or Hold?
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
$39.73 USD
-$1.54 (-3.73%)
- Volume
- 1.21M
- Average Volume
- 1.47M
- Market Capitalization
- $4.27B
- P/E Ratio
- -23.93
- Dividend Yield
- 0.00%
- Price Target
- $51.00
- Year High
- $48.40
- Year Low
- $12.30
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $22.61
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Kevin Koch |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | EWTX |
| CUSIP | 28036F105 |
| CIK | 0001710072 |
| Web | https://www.edgewisetx.com |
| Phone | 303 735 8373 |
| Currency | USD |
| Employees | 154 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 22.61 |
| Quick Ratio | 22.61 |
| Cash Ratio | 1.47 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -1.39 |
| Price / Cash Flow | -28.75 |
| Price / Book | 8.63 |
Price Target and Rating
| Average Stock Price Forecast | $51.00 |
| High Stock Price Forecast | $66.00 |
| Low Stock Price Forecast | $25.00 |
| Forecast Upside/Downside | -22.10% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 11 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.63 |
| Trailing P/E Ratio | -23.93 |
| PEG Ratio | 3.53 |
| P/E Growth | 3.53 |
| Net Income | $-167.8M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -32.55% |
| Return on Assets | -33.94% |
Financials Score
| AltmanZ Score | 109.04 |
| Piotroski Score | 2.00 |
| Working Capital | 487.25M |
| Total Assets | 518.52M |
| Ebit | -176.01M |
| Market Cap | 4.67B |
| Total Liabilities | 25.32M |
Poll Results
About Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Stock
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado. ...
2026-07-13 08:30:00
— Edgewise receives $1.55 billion in upfront cash and is eligible to receive up to $1.1 billion in regulatory and commercial milestones — — Transaction creates strategically focused cardiovascular company — — Upfront proceeds expected to fully fund EDG-7500 development through potential approval — BOULDER, Colo., July 13, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced the successful completion of its previously announced definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, acquired sevasemten and Edgewise's muscular dystrophy business for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, for aggregate potential consideration of up to $2.65 billion.
Servier finalise l'acquisition de l'activité dystrophie musculaire d'Edgewise Therapeutics
2026-07-13 08:30:00
/PRNewswire/ -- Servier, groupe pharmaceutique international indépendant gouverné par une fondation, a annoncé aujourd'hui avoir finalisé l'acquisition de
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
2026-07-01 08:00:00
BOULDER, Colo., July 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on June 30, 2026, Edgewise granted inducement stock options to purchase a total of 16,500 shares of Edgewise's common stock to 2 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").
2026-06-17 06:22:09
Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy Transcript
Edgewise Therapeutics Reports Improvements In Heart Drug Trial
2026-06-16 13:40:12
Edgewise Therapeutics Inc. (NASDAQ:EWTX) on Tuesday released topline results from the 12-week Part D cohort of its Phase 2 CIRRUS-HCM trial.
Edgewise shares slip after heart-disease drug trial data disappoints investors
2026-06-16 11:18:09
Edgewise Therapeutics shares fell nearly 10% on Tuesday after the efficacy of its experimental heart-disease drug in a mid-stage study fell short of investor expectations.
2026-06-16 07:00:00
– No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% – – Consistent and clinically meaningful improvements observed in echocardiogram parameters, biomarkers, symptoms and functional status across obstructive and nonobstructive HCM – – EDG-7500 administration continued to be generally well tolerated – – Company to host webcast today at 8:30 a.m. Eastern Time – BOULDER, Colo.
Edgewise: 'Buy' On Muscular Dystrophy Program Sale And EDG-7500 Advancement
2026-06-04 23:37:34
Edgewise Therapeutics remains a "Buy," driven by pipeline focus and a transformative $2.65B sale of its muscular dystrophy program to Servier. Company will use the $1.55B upfront cash to fully fund EDG-7500 development for oHCM/nHCM, targeting pivotal phase 3 initiation in Q4 2026. Topline 12-week Part D data from the phase 2 CIRRUS-HCM study for EDG-7500 is expected in Q2 2026, a key catalyst for advancing to phase 3.
Frequently Asked Questions
-
What is the current Edgewise Therapeutics, Inc. (EWTX) stock price?
-
Edgewise Therapeutics, Inc.(NASDAQ:EWTX) stock price is $39.73 in the last trading session. During the trading session, EWTX stock reached the peak price of $48.4 while $12.3 was the lowest point it dropped to. The percentage change in EWTX stock occurred in the recent session was --3.73% while the dollar amount for the price change in EWTX stock was -$-1.54.
-
EWTX's industry and sector of operation?
-
The NASDAQ listed EWTX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of EWTX?
-
Aylin Tugcu | Senior Vice President of Cardiovascular Clinical Development & Medical Affairs
Kevin Koch | President, Chief Executive Officer & Director
Peter A. Thompson FACP | Co-Founder & Independent Chairman
Michael Nofi | Chief Financial Officer
John R. Moore | General Counsel -
How many employees does EWTX have?
-
Number of EWTX employees currently stands at 154. EWTX operates from 3415 Colorado Avenue, Boulder, CO 80303, US.
-
Link for EWTX official website?
-
Official Website of EWTX is: https://www.edgewisetx.com
-
How do I contact EWTX?
-
EWTX could be contacted at phone #303 735 8373 and can also be accessed through its website. EWTX operates from 3415 Colorado Avenue, Boulder, CO 80303, US.
-
How many shares of EWTX are traded daily?
-
The average number of EWTX shares traded daily for last 3 months was 1.47M.
-
What is the market cap of EWTX currently?
-
The market value of EWTX currently stands at $4.27B with its latest stock price at $39.73